榮昌生物(688331.SH):實際控制人控制的企業擬增持1000萬元-2000萬元公司股份
格隆匯7月8日丨榮昌生物(688331.SH)公佈,實際控制人王威東、房健民、林健、王荔強、王旭東、鄧勇、熊曉濱、楊敏華、温慶凱、魏建良對公司經營情況的持續看好,以及對公司未來發展前景的信心,擬於2024年7月9日起6個月內,通過其控制的企業煙台榮昌控股集團有限公司以上海證券交易所交易系統允許的方式(包括但不限於集中競價、連續競價和大宗交易)增持公司股份,本次增持金額不低於人民幣1,000萬元且不超過人民幣2,000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.